[My practice of thrombolysis in the acute phase of myocardial infarction in the light of extensive studies].
Hospital mortality due to myocardial infarction has decreased markedly since the 1970's. Intravenous thrombolysis is certainly one of the reasons for this decrease but its precise role cannot be defined. In practice, major therapeutic trials enable definition of the broad lines. It is nevertheless essential to combine our personal experience with their analysis. It is not yet possible at present to say which is the best thrombolytic. Use of the association streptokinase-rtPA has the advantages of both agents and the same risks at a lower cost than that of rtPA alone.
Bory
M
M
Service de Cardiologie A, Hôpital de la Timone, Marseille.
D004359:Drug Therapy, Combination; D005602:France / Q000453:epidemiology; D006801:Humans; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000401:mortality; D013300:Streptokinase / Q000627:therapeutic use*; D015912:Thrombolytic Therapy; D010959:Tissue Plasminogen Activator / Q000627:therapeutic use*
D013300:Streptokinase; D010959:Tissue Plasminogen Activator
Ma pratique de la thrombolyse à la phase aiguë de l'infarctus du myocarde à la lumière des grandes études.